Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$87.59 USD

87.59
5,119,705

-1.18 (-1.33%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $87.59 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks News

Boston Scientific Acquires EMcision, Boosts Endoscopy Unit

Boston Scientific (BSX) adopts initiatives to strengthen the Endoscopy business.

    Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific

    Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific

      Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific

      Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific

        Millipede to Aid Boston Scientific, LOTUS Relaunch Lag Ails

        Boston Scientific's (BSX) major Millipede investment might cement the company's position in the emerging mitral regurgitation field under its structural heart business.

          Boston Scientific's (BSX) Q4 Earnings In Line, Sales Top

          Boston Scientific (BSX) has posted impressive fourth quarter results by delivering revenue growth across all segments in Q4.

            Medical Device Stocks Earnings Due on Feb 1: BSX, BAX & More

            As part of the amended tax policy, corporate tax rates are lowered to 21% from 35%, offering a huge relief to medical device giants.

              Boston Scientific's (BSX) Millipede Deal Aids MR Business

              Boston Scientific (BSX) claims the Millipede IRIS annuloplasty ring to be highly customizable to a specific patient's anatomy and disease state.

                Will WATCHMAN Boost Boston Scientific's (BSX) Q4 Earnings?

                Boston Scientific (BSX) witnesses improvement in IC arm on an innovative portfolio and robust commercial teams. The WATCHMAN platform is likely to impress with another solid quarterly performance.

                  Boston Scientific's Positive SCS Trial Aids Neuromodulation

                  Boston Scientific's (BSX) WHISPER RCT data demonstrates that sub-perception and paresthesia-based SCS therapies deliver superior results when applied as a combo regimen.

                    Boston Scientific Fortifies Pain Therapy Arm With FDA Nod

                    Boston Scientific (BSX) claims its Spectra WaveWriter Spinal Cord Stimulator System to combine both paresthesia-based and sub-perception therapies to target a specific area of pain.

                      MedTech Tax Resumes in 2018, 3 Stocks to Suffer

                      Sectors that are likely to be hampered the most by the re-imposition of the medical device tax are X-ray and MRI machines, surgical instruments and pacemakers.

                        Boston Scientific Rises 8.3% on Upbeat 4Q Preliminary Sales

                        Boston Scientific (BSX) pulls out all the stops to strengthen its core business as well as invest more in the global markets. This also gets reflected in its preliminary sales results.

                          Boston Scientific (BSX) Surges: Stock Moves 8.3% Higher

                          Boston Scientific (BSX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

                            New Products Aid Boston Scientific, LOTUS Relaunch Lag Ails

                            Boston Scientific (BSX) grows on product launches and international expansion. LOTUS relaunch delay hurts sales.

                              Boston Scientific Receives FDA Nod for Vercise DBS System

                              Boston Scientific (BSX) forges ahead with initiatives to boost DBS portfolio under Neuromodulation business.

                                Boston Scientific (BSX) Shares Drop on LOTUS Relaunch Delay

                                Boston Scientific (BSX) announces a delay in deadline for the commercial return of the LOTUS Edge Aortic Valve System in Europe. Following this news, share price declines.

                                  The Zacks Analyst Blog Highlights: Baxter International, BostonScientific, Intuitive Surgical and Becton and Dickinson

                                  The Zacks Analyst Blog Highlights: Baxter International, BostonScientific, Intuitive Surgical and Becton and Dickinson

                                    Trump Focuses on APAC: 4 MedTech Stocks to Watch

                                    Considering Trump's growing focus on APAC, the region seems to be poised to yield accretive returns over the long term. Favorable MedTech trends in APAC hold promise.

                                      Boston Scientific's (BSX) Q3 Earnings In Line, Sales Top

                                      Boston Scientific (BSX) has posted impressive Q3 results by delivering revenue growth across all segments.

                                        Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.

                                        Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.

                                          MedTech Stock Q3 Earnings Roster for Oct 26: BSX, RMD & More

                                          Investors are concerned about the Medical sector that saw a lot of struggle during the first nine months of the year, thanks to the political change and the ongoing policy-restructuring related battle.

                                            EW vs. BCR: Which Stock is Poised for Better Q3 Earnings?

                                            Political turmoil and the health policy related battle apart, majority of the MedTech stocks' bottom line is likely to be hurt in the third quarter on escalating costs induced by consecutive hurricanes and Mexico earthquakes.

                                              Will Recall Issue Hurt Boston Scientific (BSX) Q3 Earnings?

                                              Although Boston Scientific's (BSX) recent $435-million acquisition of Symetis SA might drive its IC business, the company's full recovery post a primary product recall may however, take time.

                                                Boston Scientific Grows on New Products, Currency Woe Ails

                                                Boston Scientific (BSX) is gaining traction on product launch and accretive acquisitions. Yet an unfavorable currency movement is a major dampener.

                                                  Boston Scientific's Apama Deal to Boost Electrophysiology Arm

                                                  Boston Scientific's (BSX) Apama Medical addition is expected to strengthen its suite of arrhythmia solutions under the Electrophysiology sub-segment.